Assesment of drug attitudes in patients with schizophrenia: Psychometric properties of the DAI Spanish version;Evaluación de actitudes al medicamento en pacientes con esquizofrenia: Propiedades psicométricas de la versión en español del DAI

Actas Espanolas de Psiquiatria

Volumn 32, Issue 3, 2004, Pages 138-142

  Robles Garcia R ^a,b   Salazar Alvarado, V ^a   Paez Agraz F ^a   Ramirez Barreto F ^a  

^a SECRETARÍA DE SALUD   (Mexico)

^b Inst Jalisciense de Salud Mental   (Mexico)

Author keywords

Compliance; DAI; Measures; Schizophrenia; Treatment attitudes

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT;

ADULT; ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOMETRY; QUESTIONNAIRE; RELIABILITY; SCHIZOPHRENIA; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ATTITUDE TO HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 3042656746     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Babiker IE. Noncompliance in schizophrenia. Psychiatr Dev 1986;4:329-37.
2. Curson DA, Barnes Bamber RW, Platt SD, Hirsch SR, Dutty JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine-placebo trial II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146:469-74.
3. Weiden P, Dixon L, Frances A. Neuroleptic noncompliance in schizophrenia. En: Tamminga C, Schulz C, editores. Advances in neuropsychiatry and psychopharmacology. Vol. 1. Schizophrenia research. NewYork: Raven 1991; p. 285-96.
4. García C, Sánchez D. Factores relacionados con la adherencia al tratamiento en pacientes esquizofrénicos. Actas Esp Psiquiatr 1999;27(4):211-6.
5. Weiden P, Shaw E, Mann J. Causes of neuroleptic noncompliance. Psychiatr Ann 1986;16:571-5.
6. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
7. Buchanan A. A two- year prospective study of treatment compliance in patients with schizophrenia. Psicol Med 1992;22:787-97.
8. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976;33:1443-6.
9. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomized controlled trial of compliance therapy. 18 month follow-up. Br J Psychiatry 1998;172:413-9.
10. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169:444-502.
11. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
12. Naber D. A Self rating to measure subjective effects of neuroleptic drug relationships to psychopathology quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl 3):133-41.
13. Fleischacker W, Meise U, Gúnther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;89(Suppl 382):11-5.
14. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psichol Med 1983;13:177-83.
15. Hogan TP, Award AG. Subjetive response to neuroleptics and outcome in schizophrenia: a re examination comparing two measures. Psychol Med 1992;22:347-52.
16. McEvoy JP, Appelbaum PS, Apperson LJ. Why must some schizophrenic patients be involuntarily committed? The role of insight. Compreh Psychiatry 1989;30:13-7.
17. Aguirre, Z. Variables sociodemográficas y clínicas relacionadas con el insight a tratamiento en pacientes con esquizofrenia. Tesis de especialidad en Psiquiatría de la Universidad de Guadalajara, 2003.
18. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psicol Med 1992;22:787-97.
19. Cheng HL, Yu YW. Validation of Chinese version of the «Drug Attitude Inventory». J Med Sci 1997;13(6):370-7.
20. Hogan TP, Award AG. Drug Attitude Inventory (DAI). En: American Psychiatric Association. Handbook of psychiatric measures. Washington DC: American Psychiatric Association, 2000; p. 511.
21. Wolkowitz OM, Pickar D. Benzodiazepine in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148:714-26.
22. Siris SG, Morgan V, Fagerstrom R. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 1994;44:533-9.